SIRPB1

Across TCGA pan-cancer cohorts, SIRPB1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIRPB1 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher SIRPB1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SIRPB1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

READ, BLCA, and BRCA are the cancer types where SIRPB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.082	0.799	<.001	18	view →
BLCA	OS	Median	All	0.153	0.687	.009	15	view →
BRCA	DFS	Median	III,IV	0.510	0.880	<.001	10	view →
LIHC	DFS	Median	All	0.255	0.557	.030	3	view →
SKCM	OS	Median	III,IV	0.938	0.800	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIRPB1–READ (DFS)

Open the READ breakdown →